LU90074I2 - Chlorhydrate d'irinotécan trihydraté et ses dérivés pharmaceutiquement acceptables (Campto) - Google Patents

Chlorhydrate d'irinotécan trihydraté et ses dérivés pharmaceutiquement acceptables (Campto)

Info

Publication number
LU90074I2
LU90074I2 LU90074C LU90074C LU90074I2 LU 90074 I2 LU90074 I2 LU 90074I2 LU 90074 C LU90074 C LU 90074C LU 90074 C LU90074 C LU 90074C LU 90074 I2 LU90074 I2 LU 90074I2
Authority
LU
Luxembourg
Prior art keywords
substituted
ring
group
atom
camptothecin
Prior art date
Application number
LU90074C
Other languages
English (en)
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of LU90074I2 publication Critical patent/LU90074I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LU90074C 1983-07-14 1997-06-04 Chlorhydrate d'irinotécan trihydraté et ses dérivés pharmaceutiquement acceptables (Campto) LU90074I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58126946A JPS6019790A (ja) 1983-07-14 1983-07-14 新規なカンプトテシン誘導体

Publications (1)

Publication Number Publication Date
LU90074I2 true LU90074I2 (fr) 1997-08-21

Family

ID=14947803

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90074C LU90074I2 (fr) 1983-07-14 1997-06-04 Chlorhydrate d'irinotécan trihydraté et ses dérivés pharmaceutiquement acceptables (Campto)

Country Status (8)

Country Link
US (1) US4604463A (fr)
EP (1) EP0137145B1 (fr)
JP (1) JPS6019790A (fr)
AT (1) ATE33839T1 (fr)
CA (1) CA1235415A (fr)
DE (2) DE3470744D1 (fr)
LU (1) LU90074I2 (fr)
NL (1) NL980026I2 (fr)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US6407115B1 (en) * 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
AU671605B2 (en) 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US6214836B1 (en) 1995-06-06 2001-04-10 Dr. Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US6177439B1 (en) 1995-06-06 2001-01-23 Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
US5942386A (en) * 1995-06-07 1999-08-24 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
WO1998007727A1 (fr) * 1996-08-19 1998-02-26 Bionumerik Pharmaceuticals, Inc. Derives de camptothecine hautement lipophiles
EP1011675A1 (fr) * 1997-02-27 2000-06-28 PHARMACIA & UPJOHN COMPANY Therapie au tamoxifene visant a attenuer une diarrhee declenchee par le chlorhydrate d'irinotecan
JP3046258B2 (ja) * 1997-04-11 2000-05-29 株式会社ヤクルト本社 １−クロロカルボニル−４−ピペリジノピペリジンまたはその塩酸塩の製造方法
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
EE04264B1 (et) * 1998-08-05 2004-04-15 Aventis Pharma S.A. Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6228855B1 (en) * 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US6159935A (en) * 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
BR0108728A (pt) 2000-02-28 2003-12-30 Aventis Pharma Sa Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
ATE322265T1 (de) 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
JP5409981B2 (ja) 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
WO2002034244A2 (fr) 2000-10-27 2002-05-02 Aventis Pharma S.A. Combinaison de camptothecine et d'un derive de stilbene pour le traitement du cancer
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
BR0309504A (pt) * 2002-04-26 2005-02-09 Upjohn Co Método de tratamento, prevenção ou retardo de inìcio clìnico de neoplasma, composição, método de reduzir volume ou peso de tumor
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
CN100363366C (zh) * 2002-06-27 2008-01-23 中国科学院上海药物研究所 一类喜树碱衍生物及制备方法
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
CN100344633C (zh) 2003-05-12 2007-10-24 台湾神隆股份有限公司 用于制备7－烷基－10－羟基－20(s)－喜树碱的方法
US7067666B2 (en) * 2003-06-27 2006-06-27 Research Triangle Institute 7-substituted camptothecin and camptothecin analogs and methods for producing the same
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
CA2556254A1 (fr) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Preparation de solution aqueuse contenant des camptothecines
RU2408387C2 (ru) 2004-04-27 2011-01-10 Веллстат Байолоджикс Корпорейшн Лечение злокачественного новообразования с применением вирусов и камптотецинов
PL1746976T3 (pl) 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
US20050267141A1 (en) * 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
BRPI0511753A (pt) 2004-06-01 2008-01-02 Terumo Corp formulação de irinotecano e respectiva composição farmacêutica
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
EP1796644B1 (fr) 2004-09-07 2011-04-13 Biocompatibles UK Limited Administration d'un médicament à partir d'agents emboliques
US7897772B2 (en) 2004-10-01 2011-03-01 Kabushiki Kaisha Yakult Honsha Acid addition salt of irinotecan
US7205385B2 (en) * 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
WO2006082053A1 (fr) * 2005-02-02 2006-08-10 Heidelberg Pharma Gmbh Derives d'ester d'acide gras de 7-ethyle-10-hydroxy-camptothecine
PL1846412T3 (pl) * 2005-02-07 2010-03-31 Fermion Oy Sposób wytwarzania 7-etylo-10-hydroksykamptotecyny
EP1928883B1 (fr) * 2005-02-08 2013-10-30 Fermion Oy Procede de preparation de l'hydrochlorure d'irinotecan
ES2430375T3 (es) * 2005-02-08 2013-11-20 Fermion Oy Procedimiento para la producción de cloruro de [1,4']bipiperidinil-1'-carbonilo o su clorhidrato
CN101193644A (zh) * 2005-03-04 2008-06-04 诺瓦西股份有限公司 使用蒽醌类治疗过度增殖性疾病
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
AU2006270297B2 (en) * 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP5177429B2 (ja) * 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
WO2007015259A2 (fr) * 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Procede de synthese d'intermediaires cles pour la production de derives de camptothecine
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2082741A1 (fr) 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Nouvelle forme cristalline d'hydrochlorure d'irinotécane
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
EP1803725A1 (fr) * 2005-12-13 2007-07-04 W.C. Heraeus GmbH Procédé pour la preparation d'irinotecan
US20070208050A1 (en) * 2006-02-24 2007-09-06 Palle Venkata Raghavendra Acha Process for preparing irinotecan
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
AU2007232206B2 (en) * 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
EP2061479A4 (fr) 2006-09-05 2010-08-04 Bipar Sciences Inc Inhibition de la synthèse d'acides gras au moyen d'inhibiteurs parp et méthodes de traitement associées
KR20090080046A (ko) * 2006-09-22 2009-07-23 라보팜 인코포레이트 ｐＨ 표적화된 약물 운반용 조성물 및 방법
EP2063895A2 (fr) * 2006-10-06 2009-06-03 Takeda Pharmaceutical Company Limited Médicament combiné
EP2073803B1 (fr) 2006-10-12 2018-09-19 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US20090062323A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched irinotecan
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
AU2008315048A1 (en) 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CA2705537A1 (fr) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Traitement de cancer du sein avec un inhibiteur parp seul ou en combinaison avec des agents anti-tumoraux
AU2009231804B2 (en) * 2008-03-31 2015-06-04 Boston Medical Center Corporation Predictive marker for topoisomerase I inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN101397301A (zh) * 2008-09-10 2009-04-01 重庆医科大学医药研究所 含10-羟基喜树碱的水溶性衍生物及制备方法
EP3222628A1 (fr) * 2008-12-23 2017-09-27 Gilead Pharmasset LLC Phosphoramidates nucléosidiques
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2750716A1 (fr) 2009-02-25 2010-09-02 Msd K.K. Derive de pyrimido-pyrimido-indazole
EP2403339B1 (fr) 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Thérapie de combinaison anti-cancer avec un inhibiteur de akt et d'autres agents anti-cancer
JP4750868B2 (ja) 2009-03-19 2011-08-17 株式会社日立製作所 高温下で使用されるボルトの余寿命診断方法
SI3351558T1 (sl) 2009-11-13 2020-07-31 Daiichi Sankyo Europe Gmbh Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3
CN102711837B (zh) 2009-11-18 2016-10-19 尼克塔治疗公司 盐形式的多-臂聚合物-药物偶联物
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2011116026A2 (fr) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibiteurs des interactions de liaison de sous unité alpha d'intégrine ƒà-de protéine g
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
EP2601220A2 (fr) 2010-08-06 2013-06-12 U3 Pharma GmbH Utilisation d'agents de liaison her3 dans le traitement de la prostate
EP2655401B1 (fr) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013093931A2 (fr) 2011-09-19 2013-06-27 Sun Pharma Advanced Research Company Ltd. Nouveaux promédicaments de médicaments phénoliques
RS57350B1 (sr) 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014070233A1 (fr) 2012-10-29 2014-05-08 Boston Medical Center Corporation Mutations de brca1 en tant que marqueurs prédictifs d'inhibiteurs de la topoisomérase i
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN103864810A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的10-羟基喜树碱10位衍生物制备方法及其在抗肿瘤药物中的应用
PL2979701T3 (pl) 2013-03-27 2020-12-28 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy obejmujący hydrat chlorowodorku irynotekanu
RS58067B1 (sr) 2013-03-27 2019-02-28 Taiho Pharmaceutical Co Ltd Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat u niskoj dozi
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP2881396A1 (fr) 2013-12-03 2015-06-10 Synbias Pharma AG Procédé pour la synthèse de l'irinotécan
CA2973906C (fr) * 2014-01-17 2022-07-26 Oncoral Pharma Aps Forme galenique orale solide d'irinotecan pour le traitement du cancer
EP3170005B1 (fr) 2014-07-18 2019-04-10 Sanofi Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
EP3250609A4 (fr) 2015-01-26 2018-07-11 The University of Chicago Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016203352A2 (fr) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions et méthodes de traitement du cancer
WO2016203337A2 (fr) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions et méthodes de traitement du cancer
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (fr) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Méthodes permettant de traiter le cancer du pancréas métastatique au moyen de traitements d'association comprenant de l'irinotécan liposomal et de l'oxaliplatine
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
SG11201903615WA (en) 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
CN108570057A (zh) * 2017-03-13 2018-09-25 烟台药物研究所 一种合成7-乙基-10-羟基喜树碱的方法
AU2018314227A1 (en) 2017-08-07 2020-02-06 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (fr) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer
EP3669890A1 (fr) 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
WO2020191342A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps anti-claudine-6 et conjugués de médicaments
WO2020191344A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps de claudin-6 bispécifiques
CA3136496A1 (fr) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Charbon actif hautement poreux a adsorption de medicament pour une administration de medicament amelioree
AU2020266083A1 (en) 2019-04-30 2021-09-23 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with CDK inhibitors
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
CN111171077A (zh) * 2020-01-19 2020-05-19 上海交通大学医学院附属仁济医院 喜树碱衍生物及其制备方法和应用
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Antibodies masked in protease-wells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
JPS5198300A (en) * 1975-02-20 1976-08-30 Kanputoteshin oyobi sonoruijitaino seizoho
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) * 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154583A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体

Also Published As

Publication number Publication date
EP0137145B1 (fr) 1988-04-27
DE3470744D1 (en) 1988-06-01
JPH034077B2 (fr) 1991-01-22
CA1235415A (fr) 1988-04-19
JPS6019790A (ja) 1985-01-31
DE137145T1 (de) 1985-11-21
ATE33839T1 (de) 1988-05-15
NL980026I1 (nl) 1998-11-02
NL980026I2 (nl) 1999-02-01
EP0137145A1 (fr) 1985-04-17
US4604463A (en) 1986-08-05

Similar Documents

Publication Publication Date Title
LU90074I2 (fr) Chlorhydrate d'irinotécan trihydraté et ses dérivés pharmaceutiquement acceptables (Campto)
ATE89559T1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
CA2054619A1 (fr) Derives d'aminocoumaranne, leur production et leur utilisation
NO933376D0 (no) Morfinan-derivater og medisinsk anvendelse derav
GB1303081A (fr)
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
IL103944A (en) Piperazine derivatives, their preparation and pharmaceutical compositions containing them
AU547792B2 (en) Pyrimido(5,4-d)pyrimidines
IE822330L (en) 2,2-disubstituted-ethylamines
GR3005961T3 (fr)
UA21900A (uk) Похідhі глутатіоhу або їх фармацевтичhо прийhятhі солі, які проявляють протизапальhу, протиалергійhу та гепатотропhу активhість, і спосіб їх одержаhhя
ATE55057T1 (de) Zentralwirkende muskelrelaxante.
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
FI940011A (fi) Mono- ja bis-alkyyliaminoantrasykliinit
AU5608090A (en) Amines
DE3569528D1 (en) Penem derivatives, methods of producing them, their use and pharmaceutical compositions
GB9621795D0 (en) Pharmaceutical compounds
ES8300116A1 (es) Procedimiento para la obtencion de nuevos derivados de la tiazolo (3,2-a)pirimidina
GB1490771A (en) 2-substituted 4,5-diphenylthiazoles and synthesis thereof
CA2053705A1 (fr) Derives de la piperazine
GB1064293A (en) Substituted 2-pyrrylketones
ES8305703A1 (es) Un derivado de 2-benzoilamino-bencilamina.
GB1269404A (en) 0-substituted-2,5-diphenylpyrroles
GEP19960472B (en) Method of producing derivative of quinoline or its pharmaceutically acceptable ester, or their salts
MX9703112A (es) Nitro-benzamidas utiles como agentes antiarritmicos.